Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.39 USD | -4.02% |
|
-3.63% | -24.84% |
Jun. 04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.84% | 19.4M | |
+40.80% | 53.67B | |
-8.05% | 38.76B | |
+35.79% | 38.86B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Earnings Flash (LUMO) LUMOS PHARMA Posts Q1 Revenue $165,000, vs. Street Est of $0.3M